<DOC>
	<DOCNO>NCT00449319</DOCNO>
	<brief_summary>The present therapy intend homogeneous treatment AML patient base pretreatment hydroxiurea plus induction therapy standard arm Daunorubicine accord EORTC-GIMEMA AML10 study . The post-remissional treatment base transplant HLA compatible donor foreseen patient autologous transplant without HLA compatible donor available .</brief_summary>
	<brief_title>AML Treatment Untreated Adult Patients</brief_title>
	<detailed_description>GIMEMA treatment adult ( 15-60 yr ) AML patient include 3-drug induction cycle DNR ( 50 mg/m2 1 , 3 , 5 ) , cytarabine ( 100 mg/m2 d1-10 ) , etoposide ( 100 mg/m2 d1-5 ) follow intensive consolidation cytarabine ( 500 mg/m2/q12 hrs d1-d6 ) anthracycline induction 4-6 . Following consolidation , eligible pt ( age &lt; 45 55 yr ) HLA compatible sibling allografted , others , autografted autologous peripheral stem cell ( PSC ) collect recovery consolidation . BM PB sample diagnosis centralize accord national GIMEMA original study plan aim accurately evaluate biological characteristic diagnosis identify genetic alteration prognostic relevance follow case monitor minimal disease remission . To allow adequate collection send sample start intensive chemotherapy , patient receive 5-day pretreatment consist hydroxiurea ( HU ) dosage 2 g/m2/day , also effective “ debulkying ” disease .</detailed_description>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>AML `` de novo '' bone marrow blast &lt; =30 % Performance status : 03 FAB subtype : except M3 Written inform consent age &lt; 15 year &gt; = 61 year pretreated AML chemiotherapy ( except Idrossiurea ) radiotherapy corticosteroid 7 day . diagnosis acute promyelocitic leukemia ( M3 ) Performance status = 4 Uncontrolled infection</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>61 Years</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>AML</keyword>
	<keyword>adult</keyword>
	<keyword>Hydroxyurea</keyword>
	<keyword>Transplant</keyword>
	<keyword>Toevaluate biological characteristic diagnosis .</keyword>
	<keyword>To identify genetic alteration prognostic relevance .</keyword>
	<keyword>To follow case monitor minimal disease remission .</keyword>
	<keyword>To evaluate pretreatment therapy term response rate toxicity .</keyword>
	<keyword>Disease free survival .</keyword>
	<keyword>Overal survival .</keyword>
</DOC>